Anti-inflammatory effects of PDE3/4 inhibitor ensifentrine in peripheral blood mononuclear cells from COPD patients

被引：0
|
作者：
Lea, Simon [1 ]
Li, Jian [1 ]
Littolf, Kieran [1 ]
Vijayacumaran, Kajaluckcika [1 ]
Singh, Dave [1 ]
机构：
[1] Univ Manchester, Manchester, England
来源：
EUROPEAN RESPIRATORY JOURNAL | 2024年 / 64卷
关键词：
D O I：
10.1183/13993003.congress-2024.OA2775
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD
    Cazzola, Mario
    Calzetta, Luigino
    Rogliani, Paola
    Matera, Maria Gabriella
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (10) : 827 - 833
  • [2] Ensifentrine Dual phosphodiesterase PDE3/4 inhibitor Treatment of COPD Treatment of cystic fibrosis
    Calzetta, L.
    Matera, M. Gabriella
    Rogliani, P.
    Cazzola, M.
    DRUGS OF THE FUTURE, 2019, 44 (11) : 845 - 854
  • [3] Additional Bronchodilation by Ensifentrine, A Dual PDE3/4 Inhibitor, When Combined with a LAMA/LABA in Patients with Moderate to Severe COPD
    Rickard, K.
    Rheault, T.
    Bengtsson, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [4] Ensifentrine Reduced Healthcare Resource Utilization in Subjects With COPD: Results From Enhance-2, a Phase 3 Trial of Ensifentrine, a Dual PDE3/4 Inhibitor
    Barjaktarevic, I.
    Rheault, T.
    Bengtsson, T.
    Rickard, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [5] Effect of PDE3 and PDE4 inhibitors on proliferation of human peripheral blood mononuclear cells from healthy and asthmatic donors
    Landells, LJ
    Jensen, MW
    Orr, LM
    Spina, D
    Souness, JE
    O'Connor, BJ
    Page, CP
    BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 : U87 - U87
  • [6] Anti-inflammatory effects of NO/cGMP are mediated by PDE3 inhibition in vascular smooth muscle cells
    Aizawa, T
    Wei, H
    Miano, J
    Abe, J
    Berk, B
    Yan, C
    ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (02) : 319 - 319
  • [7] Ensifentrine, A Novel, Selective Inhibitor of PDE3 and PDE4, Reduced Moderate/Severe Exacerbation Rate and Risk in Subjects With COPD Regardless of Baseline Blood Eosinophils
    Sciurba, F. C.
    Christenson, S.
    Rheault, T.
    Reyner, D.
    Bengtsson, T.
    Rickard, K.
    Barjaktarevic, I.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [8] Anti-inflammatory effect of Oyaksungisan in peripheral blood mononuclear cells from cerebral infarction patients
    Kim, Yunha
    So, Hong-Seob
    Kim, Jin-Kyung
    Park, Channy
    Lee, Jeong-Ho
    Woo, Won-Hong
    Cho, Kwang-Ho
    Moon, Byung-Soon
    Park, Raekil
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2007, 30 (06) : 1037 - 1041
  • [9] Ensifentrine, A Novel, Selective Inhibitor of PDE3 and PDE4, Improved Dyspnea in Subjects With Symptomatic, Moderate-to-Severe COPD Over 24 Weeks
    Mahler, D. A.
    Bhatt, S. P.
    Singh, D.
    Rheault, T.
    Reyner, D.
    Bengtsson, T.
    Rickard, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [10] ENSIFENTRINE, AN INVESTIGATIONAL, INHALED PDE3/4 INHIBITOR, DECREASED COPD-RELATED HEALTHCARE RESOURCE UTILIZATION OVER 24 WEEKS
    Wan, E.
    Rickard, K.
    Dixon, A.
    Davidson, J.
    Galloway, S.
    Rheault, T.
    VALUE IN HEALTH, 2024, 27 (06) : S49 - S49
12345